HOME >> MEDICINE >> NEWS
Experimental pill found to improve symptoms in patients with non-small-cell lung cancer

ORLANDO, FLA. (May 19, 2002, 12:00 p.m., EST) An experimental pill has been found to improve symptoms and quality of life in patients with non-small-cell lung cancer, according to research findings presented by Ronald B. Natale, M.D., Acting Medical Director at Cedars-Sinai Comprehensive Cancer Center, and lead author of the study. The pill, called ZD 1839 (Iressa) is one of a new class of drugs that targets and blocks a key growth signal in cancer cells.

The study, presented at the 38th annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, evaluated 216 patients with recurrent non-small-cell lung cancer who had undergone two or more rounds of chemotherapy. One group of patients received 250 mg of ZD 1839 (Iressa) daily, while the second group received ZD 1839 at 500 mg each day until the disease progressed. The investigators found that lung cancer symptoms, such as cough, shortness of breath, chest pain or tightness, appetite and fatigue, were greatly improved in about 40 percent of patients. Further, they found that symptom improvement was associated with a longer survival.

Our results show that patients who felt better after taking ZD 1839, actually lived longer than those whose symptoms did not improve, said Dr. Natale. This is important because it shows that a daily pill reduced symptoms such to the extent that many of our patients were able to resume their normal activities and enjoy life for longer.

ZD 1839 (Iressa), a pill developed by AstraZeneca, has been found to work in both laboratory and clinical trials by targeting and blocking a key growth signaling mechanism in cancer cells called the epidermal growth factor receptor (EGFR). Otherwise known as HER1, the EGFR is a part of the HER kinase family of proteins that control cell growth and can stimulate the spread of cancer when over-expressed on malignant cells.

Non-small-cell lung cancer is the most common type of lung cancer,
'"/>

Contact: Kelli Stauning
kelli.stauning@cshs.org
310-423-3674
Cedars-Sinai Medical Center
19-May-2002


Page: 1 2 3

Related medicine news :

1. St. Jude scientist wins International Society of Experimental Hematology award
2. Experimental drug improves sleep in older patients, Wake Forest Baptist study shows
3. Experimental drug used to treat recurrent ovarian cancer shows promising results
4. Experimental treatment yields new hope for children battling cerebral palsy
5. Experimental drugs show promise in halting brain tumors
6. Experimental drugs reduce neuron death in rats following insulin shock
7. Experimental drug reverses effects of Fabry disease in mice
8. Experimental peptides prevent diabetes and halt its progression
9. Experimental testosterone patch shows promise for treating diminished sexual function in surgically menopausal women
10. Clinical Trial Demonstrates Experimental Growth Factor Increases Eligibility For Autologous Stem Cell Transplantation
11. Acupuncture found to lower elevations in blood pressure

Post Your Comments:
(Date:12/15/2014)... Palm Beach, FL (PRWEB) December 15, 2014 ... Care , knows that holidays can be a daze of ... From slips and falls while decking halls, to burns when ... plenty of holiday hazards that can happen at any time. ... for pain, MD Now has made a list of helpful ...
(Date:12/15/2014)... December 15, 2014 OutMarket , ... released “ Social Media Cheat Sheets ,” a guide ... that drives results on the top ten social media ... It helps drive awareness, engagement, and customer service. It ... to make an impact on new networks and weather ...
(Date:12/15/2014)... HealthDay Reporter FRIDAY, Dec. 12, 2014 ... millions of American women who have migraine: The debilitating headaches ... no association between migraine and breast cancer risk," said lead ... Medical School. "There is no positive association, so there is ... either." About 18 percent of American women and 6 ...
(Date:12/15/2014)... The increase in prevalence of disabling hearing loss ... which is contributing to the growth in the global audiological ... of hearing loss and balance disorders are known as audiological ... speaker and amplifier. The global market is expected to grow ... period from 2014 to 2019. Some of the factors which ...
(Date:12/15/2014)... Austin, TX (PRWEB) December 15, 2014 ... with offices in 26 countries in North and South ... begun accepting responses from industry participants for its 2015 ... survey in order to identify upcoming business and market ... industry respondents. , The survey targets areas including:, ...
Breaking Medicine News(10 mins):Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2
(Date:12/17/2014)...  Beamz Interactive, Inc. (OTCQB: BZIC), a leading ... that it has signed an agreement with RSL ... innovative prosthetic, orthotic and assistive technology products and ... RSL Steeper will promote and supply the Beamz ... within UK residential care facilities through its Assistive ...
(Date:12/17/2014)... Dec. 17, 2014  IGI Laboratories, Inc. (NYSE MKT: ... of its offering of $125 million aggregate principal amount ... The Notes were offered and sold only to qualified ... Act of 1933, as amended (the "Securities Act"). ... of 3.75% per year, payable semiannually in arrears on ...
(Date:12/17/2014)... HOUSTON , Dec. 17, 2014 ... Autism Approved ( http://bit.ly/1382OkS ) program seal ... autism community. The program highlights medical practices, materials ... considered "autism-community friendly." Children affected by ... that can be exacerbated by ingredients found in ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
Cached News: